证券代码：300039 证券简称：上海凯宝 公告编号：2025-054 上海凯宝药业股份有限公司 2025 年前三季度权益分派实施公告 公司于 2025 年 11 月 18 日召开 2025 年第一次临时股东大会，审议通过的 2025 年前三季度利润分配方案为：以公司总股本 1,046,000,000 股为基数，向全体股东 每 10 股派发人民币现金红利 0.3 元（含税）。其余未分配利润结转下年。如在本公 告披露之日起至实施权益分派股权登记日前，公司总股本发生变动的，公司将按照 分配总额不变的原则对分配比例进行调整。具体内容详见公司在巨潮资讯网上披露 的相关公告。 2．本次分配方案自披露之日起至实施期间公司股本总额未发生变化。本次实施 的分配方案与股东大会审议通过的分配方案一致。 3.本次分红派息距离股东大会审议通过的时间未超过两个月。 二、权益分派方案 本公司 2025 年前三季度利润分配方案为：以公司现有总股本 1,046,000,000 股为基数，向全体股东每 10 股派 0.30 元人民币现金（含税；扣税后，通过深股通 持有股份的香港市场投资者、境外机构（含 QFII、RQFII）以及持有首发前限售 ...

证券日报网讯 11月18日晚间，上海凯宝发布公告称，选举荆树中先生担任公司第六届董事会职工代表 董事。 （文章来源：证券日报） ...

（编辑 姚尧） 证券日报网讯 11月18日晚间，上海凯宝发布公告称，上海凯宝药业股份有限公司（以下简称"公司"） 于近日收到公司首次公开发行股票并在创业板上市保荐机构东吴证券股份有限公司（以下简称"东吴证 券"）的《关于更换上海凯宝药业股份有限公司首次公开发行股票并上市持续督导保荐代表人的通知 函》：原保荐代表人刘婷女士因工作变动，不再继续履行持续督导职责，为保证持续督导工作的有序进 行，东吴证券委派翟悦女士接替公司的持续督导工作，继续履行相关职责。 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2025-052 上海凯宝药业股份有限公司 2025 年第一次临时股东大会决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1．本次股东大会未出现否决议案的情形； 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议的召开情况 1.会议召开的日期、时间： （1）现场会议时间：2025 年 11 月 18 日（周二）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 11 月 18 日上午 9:15-9:25、9:30-11:30 和 13:00-15:00；通过深圳证券交 易所互联网投票系统投票的具体时间为 2025 年 11 月 18 日上午 9：15 至下午 15:00 期间的任意时间。 2.现场会议地点：上海市工业综合开发区程普路 88 号公司三楼会议室 3.会议召开方式：以现场投票和网络投票相结合的方式召开 4.会议的召集人：公司董事会 5.会议的主持人：董事周迎宾先生（公司董事长穆竟伟女士因工作原因 ...

上海市通力律师事务所 关于上海凯宝药业股份有限公司 2025 年第一次临时股东大会的法律意见书 致: 上海凯宝药业股份有限公司 上海市通力律师事务所(以下简称"本所")接受上海凯宝药业股份有限公司(以下简称 "公司")的委托, 指派本所徐安昌律师、韩宇律师(以下简称"本所律师")根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规和规范性 文件(以下统称"法律法规")及《上海凯宝药业股份有限公司章程》(以下简称"公司章程") 的规定就公司 2025 年第一次临时股东大会(以下简称"本次股东大会")相关事宜出具法律 意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了核 查、验证。在进行核查验证过程中, 公司已向本所保证, 公司提供予本所之文件中的所有签 署、盖章及印章都是真实的, 所有作为正本提交给本所的文件都是真实、准确、完整和有效 的, 且文件材料为副本或复印件的, 其与原件一致和相符。 在本法律意见书中, 本所仅对本次股东大会召集和召开的程序、出席本次股东大会人员 资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表意见 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2025-053 上海凯宝药业股份有限公司关于 非独立董事调整暨选举职工代表董事的公告 荆树中先生辞任董事不会导致公司董事会成员低于法定最低人数，不会影响公 司董事会的正常运作，其辞任自公司收到通知之日起生效。 二、关于选举职工代表董事的情况 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《公司章程》等规定，公司于 2025 年 11 月 18 日召开职工代表大会，选举荆树中先生（简历详见附件）担任公司第六届董事会职 工代表董事，任期自职工代表大会选举之日起至公司第六届董事会任期届满之日止。 荆树中先生当选公司职工代表董事后，公司第六届董事会成员不变，公司董事会中 兼任公司高级管理人员职务的董事以及由职工代表担任的董事未超过公司董事总数 的二分之一，符合相关法律法规及《公司章程》的规定。 特此公告。 上海凯宝药业股份有限公司董事会 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、非独立董事调整的情况 上海凯宝药业股份有限公司（以下简称"公司"）于近 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记 载、误导性陈述或者重大遗漏负连带责任。 上海凯宝药业股份有限公司(以下简称"公司")于近日收到公司首次公开发行股 票并在创业板上市保荐机构东吴证券股份有限公司（以下简称"东吴证券"）的《关 于更换上海凯宝药业股份有限公司首次公开发行股票并上市持续督导保荐代表人的 通知函》：原保荐代表人刘婷女士因工作变动，不再继续履行持续督导职责，为保证 持续督导工作的有序进行，东吴证券委派翟悦女士（简历附后）接替公司的持续督导 工作，继续履行相关职责。 本次变更后，公司的持续督导保荐代表人为翟悦女士、曹飞先生，持续督导期截 止至公司首次公开发行股票募集资金使用完毕。 公司董事会对刘婷女士在担任公司持续督导保荐代表人期间所作出的贡献表示 衷心感谢！ 证券代码：300039 证券简称：上海凯宝 公告编号：2025-051 上海凯宝药业股份有限公司 关于更换持续督导保荐代表人的公告 上海凯宝药业股份有限公司董事会 2025 年 11 月 18 日 附件： 相关人员简历 翟悦女士：硕士研究生，保荐代表人，曾主持或参与卓兆点胶（920026）北交所 项目、苏盐井神（ ...

Group 1: Company Overview and Performance - Shanghai Kaibao Pharmaceutical Co., Ltd. is actively engaging with investors through performance briefings and Q&A sessions [1] - The company’s product, Tan Re Qing capsules, is a prescription drug with a medical insurance payment standard of 4.09 yuan per 0.4g capsule [1] - The overall performance of the pharmaceutical industry in Q3 2025 was influenced by macroeconomic conditions, policy adjustments, and market demand fluctuations [3] Group 2: Industry Outlook - The future of the industry is promising, driven by national strategies and policies that emphasize the development of traditional Chinese medicine (TCM) [2] - There is a growing market demand for TCM due to an aging population and increasing chronic disease prevalence, with a shift towards health management and wellness [2] - Technological innovations in standardization and quality control are enhancing the reliability and stability of TCM products [2] Group 3: Product Development and Market Potential - The new product KBZ24020 is a Class 1 new drug aimed at treating acute ischemic stroke with a market potential exceeding 90 billion yuan in the cardiovascular sector [3] - The product is still in the clinical trial phase, with potential risks related to development progress and market introduction timing [3] Group 4: Response to Health Crises - The company’s main product, Tan Re Qing injection, is included in national clinical guidelines for various infectious diseases, including avian influenza and COVID-19 [4] - The company is actively involved in addressing public health challenges through its product offerings [4]

Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]

Core Insights - Shanghai Kaibao's stock increased by 1.09% on November 11, with a trading volume of 175 million yuan [1] - The company reported a financing net purchase of 861.97 million yuan on the same day, indicating strong investor interest [1] Financing Summary - On November 11, Shanghai Kaibao had a financing buy amount of 35.90 million yuan, with a financing balance of 361 million yuan, representing 5.30% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of leverage [1] Short Selling Summary - On November 11, the company had a short selling repayment of 300 shares and a short selling amount of 1,953 yuan [1] - The short selling balance was 901,000 yuan, which is above the 50th percentile of the past year, indicating a relatively high level of short interest [1] Company Overview - Shanghai Kaibao Pharmaceutical Co., Ltd. was established on April 12, 2000, and listed on January 8, 2010 [1] - The company's main business involves the research, production, and sales of modern traditional Chinese medicine, with revenue composition as follows: injections 92.86%, capsules 5.68%, tablets 1.18%, and others 0.28% [1] Financial Performance - For the period from January to September 2025, Shanghai Kaibao reported revenue of 819 million yuan, a year-on-year decrease of 26.95% [2] - The net profit attributable to shareholders was 187 million yuan, down 13.83% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of shareholders was 49,300, a decrease of 6.04% from the previous period [2] - The average number of circulating shares per person increased by 6.43% to 18,586 shares [2]